<DOC>
	<DOCNO>NCT02658448</DOCNO>
	<brief_summary>The purpose study determine whether GTx-024 safe effective treatment stress urinary incontinence postmenopausal woman .</brief_summary>
	<brief_title>GTx-024 Treatment Stress Urinary Incontinence Women</brief_title>
	<detailed_description />
	<mesh_term>Urinary Incontinence</mesh_term>
	<mesh_term>Enuresis</mesh_term>
	<mesh_term>Urinary Incontinence , Stress</mesh_term>
	<criteria>Give voluntary , write sign , inform consent Female Age18 80 year old clinically confirm postmenopausal . Subjects must undergo onset spontaneous , medically induced surgical menopause prior start study . Spontaneous menopause define 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/ml 6 week postsurgical bilateral oophorectomy without hysterectomy SUI symptom least 6 month duration Predominant SUI ( MESA questionnaire ) 24 hour pad weight &gt; 3 gm baseline A minimum 1 SUI episode per day , 3 day diary 315 SUI episode per day , average 3 day , 3 day diary Serum AST ALT within normal limit Total bilirubin within normal limit Positive Bladder Stress Test screening Subject agree start new treatment ( medication otherwise ) know affect low urinary tract function throughout treatment follow period Subject agree maintain stable dose medication know affect low urinary tract function , include limited anticholinergic , tricyclic antidepressant , alphaadrenergic blocker , throughout treatment followup period Pelvic floor physical therapy clinical setting within 30 day prior screen History pelvic radiation treatment History urethral diverticulum History urethral sling , anterior prolapse repair , ureteral bulking agent and/or SUI procedure surgery Known vesicoureteral reflux , vaginal prolapse beyond introitus , significant urological finding , include pelvic floor abnormality , judgement investigator , could impact treatment Urinary incontinence neurogenic etilogy Patient morbidly obese ( defined 100 pound ideal body weight , body mass index 40 great ) Chronic hepatitis Hepatic cirrhosis HIV and/or hepatitis A , B , C Subjects take systemic hormone product Subjects history breast endometrial cancer Myocardial infarction arterial thromboembolic event within 6 month prior Baseline , severe unstable angina , New York Heart Association ( NYHA ) Class III IV disease , serious uncontrolled cardiac arrhythmia grade II high accord NYHA , uncontrolled hypertension ( systolic &gt; 150 and/or diastolic &gt; 100 mm Hg ) Subjects entry measurement &gt; 5 mm endometrial stripe thickness Clinically confirm urinary tract infection Any condition per investigator ' judgment may increase subject risk</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>